LungBlog

Lung cancer research done by University of Kentucky faculty members Drs. Edward A. Hirschowitz and Li Zhong continues to attract national and worldwide attention in media outlets including the Wall Street Journal and the global radio program The Voice of America.? Because of the extremely high death rate lung cancer carries, Hirschowitz, Zhong and their team have focused their research in a blood test to help identify lung cancer in high-risk people at an early and more treatable stage.

?

Nicotine replacement therapy enables a significant number of patients with chronic obstructive pulmonary disease (COPD) to stop smoking, according to a report in the August issue of Chest.

Area hospitals will be starting four sessions of the Cooper-Clayton smoking cessation program soon. The Cooper-Clayton Method to Stop Smoking program is a comprehensive, 13-week program that helps participants stop smoking with peer support, educational guidance and nicotine replacement therapy.

A Waco medical practice is one of just a few places in the country using a new technology that helps diagnose lung cancer earlier.? The system is made by an Israeli company named SuperDimension. Richie said the technology stems from work the company did for Israel?s military and was used in video games before being applied to medical equipment.

This article explores the effect of vitamin D levels on various types of cancer.

Perceptronix said Monday it has been granted approval in Canada for its ClearSign Early Lung Cancer Test.

Researchers at the Ireland Cancer Center of University Hospitals of Cleveland have found a promising, novel biomarker that may be used to predict the survival of patients with advanced lung cancer and their response to treatment.  Afshin Dowlati at the Ireland Cancer Center found that patients with a low level of the biomarker ICAM had a better chance of survival and an increased response to chemotherapy.

According to an article recently published in the journal Lung Cancer, the chemotherapy combination consisting of Eloxatin? (oxaliplatin) and Taxotere? (docetaxel) is well-tolerated and provides anticancer activity for patients with advanced non?small cell lung cancer.

Oncology specialists Poniard Pharmaceuticals have successfully enrolled 75 patients in a trial for its new drug treatment for the aggressive small cell lung cancer (SCLC).  The product called Picoplatin is an intravenous platinum-based chemotherapy drug that has been designed to overcome the problems normally associated with resistance in chemotherapy regimes using platinum compounds.  Picoplatin is Poniard’s leading candidate for a treatment for SCLC, which is the most deadly and aggressive form of lung cancer accounting for roughly 20 per cent of all cases presented to US and European doctors.

Researchers evaluate the effectiveness of a new antitumoral therapy by looking at how tumors respond to it. But in the case of advanced non-small cell lung cancer ( NSCLC ), there may be a better way to assess effectiveness. A new Southwest Oncology Group ( SWOG ) study, led by a team of researchers at University of California Davis Cancer Center, suggests that an alternative measurement – “disease control rate” – may be a more powerful predictor of survival than tumor shrinkage.